The hematopoietic system declines with age. Myeloid-biased differentiation and increased incidence of myeloid malignancies feature aging of hematopoietic stem cells (HSCs), but the mechanisms involved remain uncertain. Here, we report that 4-mo-old mice deleted for transcription intermediary factor 1γ (Tif1γ) in HSCs developed an accelerated aging phenotype. To reinforce this result, we also show that Tif1γ is down-regulated in HSCs during aging in 20-mo-old wild-type mice. We established that Tif1γ controls TGF-β1 receptor (Tgfbr1) turnover. Compared with young HSCs, Tif1γ
The hematopoietic system declines with age. Myeloid-biased differentiation and increased incidence of myeloid malignancies feature aging of hematopoietic stem cells (HSCs), but the mechanisms involved remain uncertain. Here, we report that 4-mo-old mice deleted for transcription intermediary factor 1γ (Tif1γ) in HSCs developed an accelerated aging phenotype. To reinforce this result, we also show that Tif1γ is down-regulated in HSCs during aging in 20-mo-old wild-type mice. We established that Tif1γ controls TGF-β1 receptor (Tgfbr1) turnover. Compared with young HSCs, Tif1γ
−/− and old HSCs are more sensitive to TGF-β signaling. Importantly, we identified two populations of HSCs specifically discriminated by Tgfbr1 expression level and provided evidence of the capture of myeloid-biased (Tgfbr1 hi ) and myeloid-lymphoid-balanced (Tgfbr1 lo ) HSCs. In conclusion, our data provide a new paradigm for Tif1γ in regulating the balance between lymphoid-and myeloidderived HSCs through TGF-β signaling, leading to HSC aging. T rim33/Tif1γ (tripartite motif family 33/transcription intermediary factor 1 gamma), a member of the transcriptional intermediary factor 1 family (1, 2) , is a crucial regulator of transcription during hematopoiesis (3) (4) (5) . We and others have previously demonstrated Tif1γ involvement in myeloproliferative disease (6, 7) . Mice deleted for this gene develop a substantial loss of lymphoid cells and a dramatic increase of myeloid cells (3, 6, 7) . Loss of Tif1γ favored expansion of the granulo-monocytic progenitor compartment in bone marrow (BM), which led to this lineage skewing. Furthermore, Tif1γ exerts its functions in a cellautonomous manner, as revealed by competitive transplantation experiments. With aging, mice deleted for Tif1γ develop a myeloproliferative disease involving the proliferation of immature precursors of myelocytes and monocytes (6, 7) . Therefore, the disease recapitulates important features of human chronic myelomonocytic leukemia (6) . In humans, the mean age at the onset of this disease, which is probably linked to the aging-related decreased fitness of hematopoietic stem cells (HSCs), is older than 70 y.
Changes in the biological functions of old HSCs have been directly linked to the development of several hematological disorders. The most clinically significant aspect of age-dependent hematopoietic dysfunction corresponds to the noticeable increased incidence of myeloproliferative diseases, leukemia, and other hematological diseases (8) . Adult HSCs produce all blood lineages during lifetime, but their capacity to generate lymphoid cells declines with age, whereas myelopoiesis is enhanced (9) (10) (11) . With age, HSCs in BM show an increased propensity to differentiate toward the myeloid rather than the lymphoid lineage, which may contribute to the decline in lymphopoiesis. HSC aging results from alterations of both cell-intrinsic and cell-extrinsic molecular mechanisms (12) . It has become obvious that HSCs are particularly heterogeneous, given their differentiation capacities. Indeed, some HSCs harbor a low ability to differentiate into lymphoid cells and are considered myeloid-biased, whereas other HSCs exhibit the opposite properties. Finally, a third subset of HSCs appears to maintain a balanced production and is considered to comprise balanced HSCs (13, 14) . Nevertheless, the molecular mechanisms responsible for the aging-associated increase in HSC numbers and differentiation capacities are far from being understood.
Interestingly, Tif1γ has also been implicated in TGF-β signaling through its binding to phosphorylated small mother against decapentaplegic (Smad)2/3 (4, 15) and to Smad4 to promote its ubiquitination (16) (17) (18) . Moreover, TGF-β signaling pathways have long been known to be involved in modulating HSC quiescence (19, 20) , partly by preventing HSC reentry into the cell cycle (21) . Myeloid-and lymphoid-biased HSC populations seem to respond differently to TGF-β signaling (22) . Therefore, the mechanisms by which age-related differences in HSCs are affected by TGF-β need to be characterized.
Deciphering how aging-associated changes within the hematopoietic system influence leukemia development will be crucial for the development of therapeutic strategies. As there are important similarities between the physiological aging of hematopoiesis and the HSC premature aging phenotype observed in young Tif1γ
−/− mice, here we used this newly established model to investigate the effect of Tif1γ on hematopoietic aging at the physiological, cellular, and molecular levels.
Results
An Accelerated Aging-Like Phenotype Is Observed in Tif1γ −/− Hematopoiesis. To determine whether Tif1γ −/− mice developed a premature aging-like phenotype, we analyzed HSCs isolated from the BM of 4-mo-old Tif1γ −/− mice and compared them with HSCs isolated from 20-mo-old (old) and 4-mo-old (young) wild-type (wt) mice. The number of long-term HSCs defined by signaling Significance Hematopoietic stem cell aging has been directly linked to the development of several hematological disorders, including myeloproliferative diseases. Here we show that in elderly mice (20 mo old), physiological aging of the hematopoietic system is linked to a decreased expression of transcription intermediary factor 1γ (Tif1γ) in HSCs. In turn, in young Tif1γ −/− mice (4 mo old), the hematopoiesis aging phenotype is exacerbated. In both sets of mice, Tif1γ level controls the TGF-β receptor 1 (Tgfbr1) turnover and subtly regulates the number of myeloid-biased HSCs in bone marrow. We establish that young Tif1γ −/− mice develop a phenotype of premature hematopoietic aging that may explain their predisposition to myeloproliferative disease. −/− mice and in old wt mice than in young wt mice, which is consistent with aging in hematopoiesis (Fig. 1A) . Despite their proliferation in BM, HSCs showed a decreased capacity to differentiate and generate white cells in peripheral blood (PB), which also corroborates the aging phenotype of HSCs (Fig. 1B) . We characterized the proportion of mature hematopoietic cells in PB and found that Tif1γ −/− HSCs displayed an increased propensity to differentiate toward myeloid, rather than lymphoid, lineages, which contributes to the decline in lymphopoiesis that accompanies aging (Fig. 1C) . The decreased fitness of HSCs that occurs during aging led to an increased number of myeloid cells (>2,500 × 10 3 /mm 3 in PB) for ∼60% of the wt mice reaching 20 mo of age (Fig. 1D ). This phenotype is accelerated in Tif1γ −/− mice, whereas ∼60% of them older than 4 mo already showed a myeloid cell count higher than 2,500 × 10 3 /mm 3 ( Fig.  1E) . Hemocytometry also confirmed that young Tif1γ −/− and old wt mice showed very similar distributions for populations of granulocytes and monocytes (Fig. 1F) . Because the accumulation of DNA repair defects characterizes aging of HSCs (23, 24) , we quantified phosphorylation of the histone variant H2AX (γH2AX), a well-established indicator of DNA double-strand breaks, in SLAM cells by immunostaining. We found an increased number of DNA foci, which support the genomic instability in SLAM cells from Tif1γ −/− mice (SI Appendix, Fig. S1 ). The HSC population enters the cell cycle more frequently in old mice, which might be related to the increased incidence of leukemia (25, 26) .
Interestingly, young Tif1γ −/− mice also showed elevated proliferation of the LSK cells containing HSCs and multipotential progenitors (SI Appendix, Fig. S2 ). Because current evidence links telomere shortening to aging and stem cell dysfunction (27) , we measured the absolute telomere length and observed that both Tif1γ −/− and old LSK cells were characterized by a telomere shortening compared with young LSK cells (SI Appendix, Fig. S3A ). Furthermore, the regulator of telomere length (Rtel1) mRNA involved in regulation of telomere size (28) was down-regulated in both Tif1γ
−/− and old LSK cells compared with young cells (SI Appendix, Fig. S3B ). Altered hematopoiesis in aging might also be a result of changed interactions of aged stem cells with the microenvironment. Although old HSCs have been described to localize more distantly to the endosteum (29), we also observed an altered endosteal location of Tif1γ −/− HSCs, which reinforces the aged phenotype associated with HSCs (SI Appendix, Fig. S4 ). Hence, an accelerated aging-like phenotype occurs in hematopoiesis of Tif1γ −/− mice.
Tif1γ −/− Primitive Hematopoietic Cells Shows Alterations in Gene
Expression Programs Comparable to Physiological Aging. To determine whether Tif1γ −/− and old HSCs share the same gene expression changes, we purified 200,000 LSK cells and performed high-throughput mRNA sequencing (RNA-seq). Statistical analysis uncovered 2.3% and 3.9% of the genes that were reciprocally up-regulated and down-regulated between young and Tif1γ −/− libraries (P < 0.25). Interestingly, 20% of the upregulated genes and 26% of the down-regulated genes were differentially expressed during the physiological aging of HSCs (comparing the young versus the old libraries; P < 0.25; SI Appendix, Fig. S5 ). Using gene ontology clustering, we identified modulations of gene expression in different processes, such as transcription, signaling, RNA processing, growth and cell cycle, cytoskeleton, chromosome and telomere structure, cell adhesion and migration, metabolism and endocytosis/transport, and finally in response to cytokines and immune signaling (SI Appendix, Table S1 ). Two of these clusters were particularly pertinent: Tif1γ −/− and old HSCs shared the same lipid metabolism (SI Appendix, Fig. S6 ) and reduced expression of several growth factor receptors involved in hematopoiesis (SI Appendix, Fig.  S7 ). Therefore, we can conclude that Tif1γ
−/− hematopoietic cells show alterations in gene expression programs similar to physiological aging.
Tif1γ Expression Decreases in HSCs During Aging. We isolated SLAM cells from either young or old wt mice and observed that Tif1γ mRNA was down-regulated during aging ( Fig. 2A) . To measure Tif1γ expression at the clonal level, single-SLAM cell gene expression analysis was performed as previously described (30) . Although Tif1γ mRNA was detectable in more than 75% of these cells in young mice, only 37% of the clones in old mice expressed Tif1γ (Fig. 2B ). Among the clones showing detectable levels of Tif1γ, the relative expression was found to be downregulated during aging (Fig. 2C ). Because the Tif1γ promoter contains a CpG-rich region, we analyzed the DNA methylation level of the Tif1γ promoter obtained from the DNA of sorted LSK cells of young and old mice, but no methylation was detected on the studied CpGs (SI Appendix, Fig. S8A ). Quantitative chromatin immunoprecipitation assays on LSK cells revealed that global levels of acetylation of histone H3 at lysine 14 were −/− mice younger than 4 mo (n = 45) and older than 4 mo (n = 48). Percentage of mice for which the total count of myeloid cells was more than 2,500 × 10 3 /mm 3 is reported. (F ) Mice were divided into three groups, according to whether they showed increased monocytes (mono), granulocytes (granulo), or monocytes plus granulocytes (mono+ granulo). Monocytes and granulocytes measured (%) by hemocytometry in PB.
markedly decreased on the promoter of Tif1γ in old HSCs (SI Appendix, Fig. S8B ). Collectively, these results demonstrate that the down-regulation of Tif1γ correlates with posttranslational modifications of histones. −/− and old wt mice exhibited myeloid-biased differentiation, which is characterized by an expanded production of granulocytes and monocytes, as well as a decreased percentage of B and T lymphocytes (Fig. 3A) . These changes in mature hematopoietic cells were associated with profound alterations of early hematopoiesis in BM. Twentyfour weeks after transplantation, the proportions of donorderived megakaryocyte-erythroid progenitors, common myeloid progenitors, and common lymphoid progenitors were significantly reduced, whereas donor-derived granulocyte-monocyte progenitors were found to have proliferated (Fig. 3B) . Pre/proB and proE in Tif1γ −/− BM also displayed identical behavior with those in physiologically aged BM (SI Appendix, Fig. S9 ). Tif1γ
and old SLAM cells exhibited decreased reconstitution potential in BM compared with young SLAM cells (Fig. 3C ). This also corroborates the deficient fitness observed in HSCs during aging. Together, these results indicate that Tif1γ deficiency leads to a cell-autonomous reduction in the ability of long term (LT)-HSCs to generate the earliest lymphoid and erythroid progenitors and in their capacity to produce more myeloid progenitors, which is phenotypically consistent with the aging of HSCs. We next carried out a clonal analysis of HSC expansion by transplanting single SLAM cell into lethally irradiated recipient mice together with support cells depleted from Sca-1 + HSCs. Longterm reconstitution was characterized 16 wk after transplantation, and the contribution of the clone was subdivided according to the granulocytes+monocytes/(B+T lymphocytes) [GM/(B+T)] ratio observed in PB to discriminate myeloiddominant from lymphoid-dominant clones (13, 14) . Myeloiddominant clones represented 25% of the clones in young mice, and this population of myeloid-biased SLAM cells was found to be markedly increased in old wt and young Tif1γ −/− mice; that is, these myeloid-restricted SLAM cells corresponded to 74% and 89% of the clones, respectively (Fig. 3D) . Moreover, although myeloid-biased clones exhibited low contributions to the total circulating WBC (0.1-5%), lymphoid clones showed higher contributions (>5%). This finding provides evidence that Tif1γ finely controls the proportion of lymphoid/myeloid-derived HSCs.
Tif1γ Regulates the Tgfbr1 Level on HSCs. Direct molecular studies of HSCs are hampered because of their low number in hematopoietic tissues. Thus, to elucidate a definite functional role for Tif1γ, we immortalized Tif1γ −/− HSCs (Fig. 4A) . We purified LSK cells, which are enriched in HSCs and transduced them with the retroviral construct encoding the NUP98-HOXA9 oncogene. Wt HSCs were also isolated to immortalize control HSCs. Both cell lines were easily grown in medium supplemented with IL-3, IL-6, and stem cell factor (SCF). Because Tif1γ has been shown to affect cell response to the TGF-β superfamily in different tissues (4, (16) (17) (18) , we administered recombinant TGF-β1 to the cells. It turned out that this ligand had a considerable antiproliferative effect on the Tif1γ −/− line, but not on the wt line (Fig. 4B) , thus supporting the hypothesis that loss of Tif1γ would make HSCs more sensitive to TGF-β1. Tif1γ has been described as acting as an E3 ubiquitin ligase on Smad4 to regulate the TGF-β pathway (16, 17) . We decided to test the administration of recombinant Activin A, also known to stimulate Smad4 signaling (31) . Interestingly, exposure to Activin A did not have an antiproliferative effect on Tif1γ −/− cells (Fig. 4B) . Therefore, the increased sensitivity of the Tif1γ −/− line to TGF-β1 cannot be explained by the control of the intracellular level of Smad4 protein by Tif1γ. This is corroborated by the fact that Smad4 was not differentially expressed in the Tif1γ −/− line compared with the wt line (Fig. 4C) . Although the Tif1γ −/− line was only sensitive to TGF-β1 and not to Activin A, we examined the protein expression of the TGF-β receptor 1 (Tgfbr1, Alk5). Surprisingly, its expression was more than 4 times greater in the Tif1γ −/− line compared with in the wt line (Fig. 4 C and D) . As both cell lines expressed the same level of Tgfbr1 mRNA (Fig. 4E) , we hypothesized a posttranscriptional regulation of Tgfbr1. Indeed, the Tgfbr1 protein was very stable in the Tif1γ −/− line (SI Appendix, Fig. S10 ). In addition to its role as a transcription factor, Tif1γ is known to display polyubiquitin ligase activity (16, 17) . To determine whether Tif1γ could regulate Tgfbr1 through ubiquitinylation, both lines were treated with MG132, a proteasome inhibitor. Pull-down assays showed that polyubiquitinylation of Tgfbr1 in the Tif1γ −/− line was lower than that in the wt line (Fig. 4F) . Thus, Tif1γ regulates the TGF-β1 receptor turnover via its ubiquitin ligase activity.
Tgfbr1 Level Is Increased on SLAM Cell Isolated From Young Tif1γ
−/− and Old WT Mice. To establish a correlation between the increased level of Tgfbr1 in Tif1γ −/− HSCs and physiological aging of HSCs, we isolated SLAM cells from Tif1γ −/− mice and old or young wt mice. Tgfbr1 expression demonstrated that SLAM cells harboring high levels of the TGF-β1 receptor (Tgfbr1 hi cells) were positive for phospho-Smad2/3, which indicated greater activation of the TGF-β pathway (Fig. 5) . A higher percentage of the Tgfbr1 hi SLAM cell subset was observed in Tif1γ −/− (48.8%) and old wt SLAM (47.2%) cells than in young wt SLAM cells (22.1%).
Tif1γ
−/− and Old HSCs Are Very Sensitive to TGF-β Signaling. We gave three i.p. injections of 5 μg/kg TGF-β1 24 h apart and analyzed PB 48 h after the last injection. As reported (22) , exposure to TGF-β1 stimulated myeloid-HSCs with a significant increase in myeloid cells in young wt mice (Fig. 6A) . In contrast, we observed a striking reduction in myeloid cell production in both Tif1γ −/− and old mice treated with TGF-β1 (Fig. 6A) . The TGF-β signaling pathway has long been implicated in regulating HSC quiescence (19, 20, 32) . Although Tif1γ − /− and old HSCs expressed high levels of Tgfbr1, we analyzed the effect of high dose of TGF-β1 on HSCs. We also observed an increased proportion of dormant HSCs in BM from Tif1γ −/− and old mice treated with recombinant TGF-β1, whereas the treatment did not affect the quiescence of young HSCs (SI Appendix, Fig. S11 ). TGF-β is generally cataloged as one of the most potent inhibitors of HSC growth (31) . Several molecular mechanisms have been proposed to account for TGF-β-mediated growth inhibition, including up-regulation of cyclin-dependent kinase inhibitors, among which p57 has been identified as the most significantly up-regulated by TGF-β (19) . After injection of recombinant TGF-β1 in vivo, HSCs exposed to a high level of TGF-β1 were analyzed ex vivo, and we observed an important up-regulation of p57 in Tif1γ
−/− and old HSCs compared with young HSCs (SI Appendix, Fig. S12 ). Although Tif1γ −/− and old HSCs expressed a high level of Tgfbr1, they were more sensitive to TGF-β signaling under a high dose of TGF-β1 and were subject to antiproliferative effect and became more dormant in BM, which explains the reduced number of myeloid cells in PB. A high level of TGF-β1 has therefore rescued the biased myeloproliferation in old and Tif1γ −/− mice. Importantly, this effect was reversed on addition of the TGF-β type I receptor inhibitor SB431542, which is known to remove HSCs from their quiescence, and therefore intensified the myeloproliferation in Tif1γ −/− and old mice (SI Appendix, Fig. S13 ). To accurately assess the in vivo response of HSCs to TGF-β1, we competitively transplanted 200,000 CD45.2 BM cells isolated from Tif1γ −/− , old or young mice, with 200,000 CD45.1 young supported BM cells. After stable hematopoietic reconstitution (12 wk posttransplantation), the mice were injected with 5 μg/kg TGF-β1 (Fig. 6B) . TGF-β1 caused a slight expansion of the young donor population and significantly affected the expansion of both Tif1γ −/− and old donor cells. Furthermore, although the injection of TGF-β1 produced a significant stimulatory myeloid proliferation of the young donor cells, it blocked the myeloid proliferation of both Tif1γ −/− and old donor cells.
Identification of Myeloid-Biased HSCs Expressing a High Level of
Tgfbr1. To provide evidence of heterogeneity and to discriminate HSCs according to Tgfbr1 expression, we prospectively isolated two subpopulations of SLAM cells expressing Tgfbr1 with either high (Tgfbr1 hi ) or low (Tgfbr1 lo ) rates (Fig. 7A) . Remarkably, Tif1γ mRNA expression was decreased in Tgfbr1 hi SLAM cells (Fig. 7B) . Sorted cells were isolated from CD45.1 mice and transplanted in a competitive manner into CD45.2 mice. Sixteen weeks after transplantation, Tgfbr1
hi SLAM cells showed a significantly lower contribution to the total circulating WBC, with 13% versus 35% obtained with Tgfbr1 lo SLAM cells (Fig. 7C) . Although Tgfbr1 lo SLAM cells reconstituted both myeloid and lymphoid lineages, Tgfbr1
hi SLAM cells exhibited myeloid-biased differentiation, which is characterized by the exclusive production of myeloid cells in PB and very low reconstitution of both B and T lymphoid lineages (Fig. 7D) . Tgfbr1 hi SLAM cells displayed an increased propensity to generate more granulocyte-monocyte progenitors and a reduced capacity to produce the earliest common lymphoid progenitors and megakaryocyte-erythroid progenitors (SI Appendix, Fig.  S14 ). When we analyzed BM from mice reconstituted with either Tgfbr1 lo or Tgfbr1 hi SLAM cells, donor Tgfbr1 lo SLAM cells were twice as represented as Tgfbr1 hi SLAM cells (Fig. 7E ), indicating that Tgfbr1 hi SLAM cells displayed a reduced propensity to reconstitute the hematopoietic system under competitive transplantation settings. However, the percentage of donor-derived Lin − cells did not show any significant difference (Fig. 7F) . Therefore, Tgfbr1 hi SLAM cells produce more donorderived progenitors. In conclusion, Tgfbr1 hi SLAM cells share several features with SLAM cells isolated from both old and Tif1γ −/− mice. Tgfbr1 is a novel positive marker of myeloidderived HSCs (Fig. 7G) .
Discussion
We confirmed reports describing an alteration in the composition of the HSC compartment during aging and provided support to the idea that aging modifies the clonal composition of the HSC compartment because of a relative expansion of myeloidbiased HSCs (13, 14, 22, 33, 34) . We proved that young Tif1γ
HSCs supported stem cell-autonomous parameters of HSC aging. When HSCs were transplanted into recipient mice, they exhibited similar properties of deficient competitive fitness, reduced ability to produce lymphoid and erythroid progenitors, and increased capacity to generate more myeloid progenitors.
In our single-cell transplantation assay, myeloid-biased clones did not contribute much to WBCs (0.1-5%), whereas lymphoid/ myeloid-balanced clones made a greater contribution (>5%). This finding underlines the small contribution of SLAM cells in old and Tif1γ −/− mice to total circulating WBC compared with the higher contribution of young SLAM cells.
We demonstrated for the first time to our knowledge that two populations of HSCs coexist, depending on the level of expression of the TGF-β1 receptor. Remarkably, using Tgfbr1 as a marker to discriminate between HSC-containing populations in transplantation studies, we provided evidence of the capture of myeloid-biased (Tgfbr1 hi HSCs) and myeloid-lymphoid-balanced HSCs (Tgfbr1 lo HSCs). We found that myeloid-biased Tgfbr1 hi cells became the dominant HSC subtype in young Tif1γ −/− mice, which developed a premature hematopoietic aging phenotype, and in old mice during physiological hematopoietic aging. Indeed, in young mice, one fifth of the SLAM cells expressed Tgfbr1 hi , whereas this proportion increased significantly to reach almost half of HSCs in both Tif1γ
−/− and old wt mice. Tgfbr1 hi SLAM cells generated more progenitors in BM, but those progenitors have reduced contribution to the total circulating WBC. Important hematopoietic growth factor receptors were repressed in Tif1γ
−/− and old HSCs. Remarkably, some of them are known to be down-regulated by TGF-β1. First, the expression of IL-3 and IL-6 receptors is inhibited by TGF-β1 (35, 36) , and both IL-3 and IL-6 are markers in the differentiation/activation of lymphocytes. Second, TGF-β1 is known to transcriptionally repress the class II transactivator, which down-regulates the class II MHC expression (37, 38) . Third, TGF-β1 inhibits the IFNinduced signaling (12, 39) . Notably, the IFN-inducible gene Irf8 has been identified as one of the most relevant down-regulated markers in aging HSCs (40) , and Irf8 −/− mice had significantly increased myeloid cell number (41). In conclusion, increased TGF-β signaling reduces the expression of further signaling growth factors and potentiates myeloid cell commitment.
Tif1γ can act as an E3 ubiquitin ligase on Smad4 to regulate the TGF-β pathway (16, 17) . We therefore tested the effect of two ligands (TGF-β1 and Activin A) that activate Smad4 signaling (31, 42) and showed that the increased sensitivity of Tif1γ −/− hematopoietic cells to TGF-β was not related to intracellular Smad4 protein, and that Tif1γ −/− cells were only sensitive to TGF-β1 and not to Activin A. We revealed that Tif1γ regulates the TGF-β signaling by controlling the level of the TGF-β receptor 1 in hematopoietic cells. Even though Tif1γ has been reported to act as a crucial regulator of transcription during hematopoiesis (3, 5), we found no evidence of transcription regulation of the Tgfbr1 gene in Tif1γ −/− hematopoietic cells. Nevertheless, we highlighted that Tif1γ modulated Tgfbr1 polyubiquinylation and turnover. Importantly, TGF-β1 receptor signaling and turnover have been reported to be controlled by other E3 ubiquitin ligases in several tissues (43, 44) .
The accumulation of DNA damage is a marker of HSC aging (23, 24) . Tif1γ is required for efficient DNA repair, as Tif1γ-deficient cells show enhanced sensitivity to DNA damage (45) . During aging, HSC expressed lower levels of Tif1γ and consequently increased frequency of histone γH2AX DNA repair. Our study also suggests that the role of Tif1γ on the Tgfbr1 regulation was probably not directly involved in DNA damage response but, rather, only in the control of the myeloid HSC expansion. The injection of a high dose of TGF-β1 significantly stimulates myeloid proliferation of young donor cells (22) . Our data corroborated this when young recipient mice were treated with high dose of TGF-β1. In old wt and young Tif1γ −/− mice, HSCs expressed a higher level of the TGF-β1 receptor, indicating their greater sensitivity under a physiological level of TGF-β. As a consequence, this leads to myeloid proliferation at low rate of TGF-β. Conversely, under a high dose of TGF-β1, Tif1γ
−/− and old wt myeloid HSCs become too sensitive to TGF-β1, stop their proliferation, and enter quiescence.
In summary, this study unveils an unsuspected role for Tif1γ in controlling TGF-β receptor 1 signaling to finely control the proportion of lymphoid/myeloid-derived HSCs and suggests more broadly its mechanistic role in HSC aging through the TGF-β signaling pathway. Changes in the biological function and decreased fitness of old HSCs have been directly linked to the development of several hematological disorders. Here, we characterized the first physiological step that may lead to the development of a myeloproliferative disease in Tif1γ −/− mice through the premature aging of HSCs.
Materials and Methods

Tif1γ
−/− mice were genotyped according to described procedures (6) . Purified cells were sorted at indicated doses and mixed with 2 × 10 5 unfractionated support BM cells from a congenic strain. For single-cell transplantation, recipient mice were transplanted with Sca-1-depleted support BM cells. Cells were transplanted into the tail vein of lethally irradiated (900cGy) recipients. PB was collected from the tail vein. Erythrocytes were lysed with NH 4 Cl, and remaining WBCs were analyzed by FACS. Hematologic cells were counted using a hemocytometer (SCIL Vet ABC + ). Three doses of 5 μg/kg TGF-β1 at 24 h apart (22) were injected into the tail vein of Tif1γ −/− , old and young mice, or in secondary recipients, 12 wk posttransplantation. PB or BM were then monitored 48 h after the last injection. Statistics, molecular, biological, and other analyses were performed as described in SI Appendix, Materials and Methods.
